Download - News Explained: Why did the Indian Patent Office reject J&J’s application to extend its patent on an anti-TB drug?

Discover

Podcast Features
Your all-in-one podcasting solution.

Blog to Podcast
Turn your blog into an engaging podcast.
Livestream
High-performing audio live, without limits.

Podcast Studio
Easy-to-use audio recorder app.
Podbean AI
AI-Enhanced Audio Quality and Content Generation.

Podcast App
The best podcast player & podcast app.

Ads Marketplace
Join Ads Marketplace to earn money
through sponsorship on your podcast.

PodAds
Manage your ads with dynamic ad insertion capability.
Apple Podcasts Subscriptions Integration
Effortlessly publish and manage exclusive episodes for your
Apple Podcasts subscribers directly from Podbean.
Live Streaming
Receive livestream rewards from your audience and earn
recurring income from your Fan Club membership.

All Arts Business Comedy Education
Fiction Government Health & Fitness History Kids & Family
Leisure Music News Religion & Spirituality Science
Society & Culture Sports Technology True Crime TV & Film
Live

How to Start a Podcast
How to Start a Live Podcast
How to Monetize a podcast
How to Promote Your Podcast
How to Use Group Recording

Log in
Start your podcast for free

Podcasting
Monetization
Advertisers
Enterprise
Pricing
Discover

BusinessLine Podcasts

News:Business News

News Explained: Why did the Indian Patent Office reject J&J’s application to extend its patent on an anti-TB drug?

2023-03-24

Download Right click and do "save link as"

The Indian Patents Office on Thursday rejected an application of global pharma major Johnson and Johnson seeking an extension of its patent on anti-Tuberculosis (TB) drug Bedaquiline beyond July 2023, when it is set to expire. Why is this significant? Will it help TB patients in India? The Hindu businessline's Senior Deputy Editor G Naga Sridhar explains in this episode of News Explained. Tune in to know more.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/business-line/message